We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
FDA Awards Breakthrough Therapy Designation to Boehringer’s Lung Cancer Candidate
News

FDA Awards Breakthrough Therapy Designation to Boehringer’s Lung Cancer Candidate

FDA Awards Breakthrough Therapy Designation to Boehringer’s Lung Cancer Candidate
News

FDA Awards Breakthrough Therapy Designation to Boehringer’s Lung Cancer Candidate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FDA Awards Breakthrough Therapy Designation to Boehringer’s Lung Cancer Candidate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BI 1482694 is a third-generation EGF mutant-specific tyrosine kinase inhibitor that has demonstrated strong anti-tumor activity and a favorable safety profile in patients whose tumors have stopped responding to currently available EGFR-directed therapies, according to the company.

The FDA awarded the designation based on results from Phase 1/2 clinical trial presented at the ESMO Asia 2015 Congress in Singapore.

Boehringer has an exclusive license and collaboration agreement with Hanmi Pharmaceutical for the development and commercial rights to BI 1482694, except in South Korea, China and Hong Kong.

Advertisement